Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy

Publication Date: November 1, 2021

Key Points

Key Points

  • Immunotherapy has revolutionized the treatment of many different types of cancers.
  • Immune checkpoint inhibitors (ICPi) targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), and PD ligand 1 (PD-L1) work by preventing the receptors and ligands from binding to each other, thereby disrupting signaling so that T-cells can recognize and attack cancer cells. They are currently the standard of care in the treatment of several cancers, including a variety of solid-organ and hematological malignancies.
  • The use of ICPis is rising exponentially, with approximately 40% of patients with cancer in the United States in 2019 eligible for treatment with ICPis.
  • Immune checkpoint blockade therapy is associated with a spectrum of side effects that is quite different from other systemic therapies such as cytotoxic chemotherapy.
    • Moderate to severe immune-related adverse events (irAEs) may be associated with life-threatening declines in organ function and quality of life, and fatal outcomes have been reported.

Key Recommendations

...y Recommendation...

...g are general recommendations that...


...ecommended that clinicians manage to...


...mmendations in this guideline are conse...


Treatment

Treatment

...ble A2: Immunosuppressive AgentsHaving trouble...


...3. Commonly Conducted Testing at Baseli...


...ommonly Conducted Testing During irAE Manage...


...e 1. Cutaneous ToxicitiesHaving trou...


...le 2. Gastrointestinal (GI) Toxiciti...


...able 3. Lung ToxicitiesHaving troub...


...ndocrine ToxicitiesHaving trouble viewing t...


.... Musculoskeletal ToxicitiesHaving trouble view...


...ToxicitiesHaving trouble viewing table?...


...ous System ToxicitiesHaving trouble viewi...


...Hematologic ToxicitiesHaving trouble viewi...


...9. Cardiovascular ToxicitiesHaving trouble...


...0. Ocular ToxicitiesHaving trouble viewing table?...